Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
SAN DIEGO, Jan. 04, 2018 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018 at 8:00 a.m. Pacific Time. The conference will be held at the Westin St. Francis in San Francisco, CA.
Links to a live audio webcast and replay of the presentation may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for 90 days following the event.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated three innovative and unique development programs based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr’s two clinical-stage programs, ATYR1940 (Resolaris) and ATYR1923 (iMod.Fc), are agonists of the Resokine pathway designed to temper immune engagement in diseases characterized by excessive immune cell involvement in muscle and lung. aTyr’s third program, ORCA, represents a pre-clinical research program that targets a novel, proprietary immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 220 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit http://www.atyrpharma.com.
Contact:
Mark Johnson
Sr. Director, Investor Relations
[email protected]
858-223-1163
